Categories Earnings, Leisure & Entertainment

Global Eagle Entertainment (NASDAQ: ENT): Q4 2019 Earnings Snapshot

— Global Eagle Entertainment Inc. (NASDAQ: ENT) reported a fourth-quarter 2019 loss of $0.39 per share versus a loss of $0.34 per share expected.

— Revenue rose by 1.4% year-over-year to $163 million versus $165.05 million expected. This was driven by a 26.3% growth in connectivity equipment revenue from increased aircraft installations.

Earnings Update by AlphaStreet

— Gross margin improved 4.6 percentage points driven by the activation of additional aircraft on its network, growth in services to cruise markets, and improved management of network costs.

— The company is implementing its previously disclosed phase 3 cost initiatives in the first half of 2020. Phase 3 initiatives will target business process reengineering and procurement initiatives. Phase 3 is expected to generate more than $10 million of additional savings during 2020.

— The company expects the Boeing 737 MAX aircraft in its fleet of connected aircraft to resume normal operations in the second half of 2020. The company’s MAX-connected aircraft remained grounded during the fourth quarter due to regulatory actions.

— Global Eagle continues to forecast that MAX program issues will impact services revenue, including both Connectivity and Media & Content revenue, by about $3 million per quarter, with an Adjusted EBITDA impact of about $2 million per quarter.

— Due to the production halt of the aircraft, the company expects between 10 and 15 fewer aircraft installations per quarter. The impact on equipment revenue is expected to be about $4-5 million per quarter with a gross margin impact of around 20%.

— Due to limited data, the company believes that it is too early to quantify the impact of the Covid-19 outbreak on the travel industry, its operations or its financial performance.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top